When the generative AI program ChatGPT rolled out last year, H1 CEO and co-founder Ariel Katz instantly saw its potential to improve his company’s Trial Landscape platform, a database designed to accelerate clinical trial planning and design.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,